Beta Drugs Ltd

- Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year. - The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years. - EBITDA margins are expected to be stable around 23% to 25% consolidated. - The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs. 45-50 crores in sales in 3 years. - The Company forecasts consolidated revenue to reach approximately Rs. 750 crore by 2027-28. - Net profit rose from Rs. 36.43 crore to Rs. 45.83 crore in FY '25 excluding one-time expenses. - The focus remains on sustainable growth, balancing topline and bottom-line improvements with margin stability.

- The company recently raised approximately Rs. 117 crores through a preferential issue involving convertible debentures, which carry a coupon leading to higher interest costs. - As of now, the funds from this issuance are largely parked in fixed deposits, with around Rs. 11 crores utilized for facility upgrades. - There is no mention of any immediate new fundraising plans through debt or equity. - The management is exploring growth opportunities, including possible M&A, but currently, there is nothing concrete on the table. - Expansions planned include new corporate building for regulatory and R&D functions, and intermediate manufacturing capacity. - The company seems well capitalized with a healthy cash position, focusing on utilizing existing raised funds for growth and expansion rather than raising new funds immediately.

- Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place. - Investment of approximately Rs. 11 crores has been made in facility upgrades, mainly in Adley Formulations and Adley Lab. - The Company is actively looking for land or a plant for backward integration to manufacture intermediates, reducing dependency on China and ensuring a reliable supply chain for KSMs. - R&D team has around 10 people currently, with ongoing investment in scientific and drug delivery system innovations. - Potential strategic investments/M&A will be considered if good branded businesses become available, though there is nothing concrete on the table currently. - Funds of around Rs. 117 crores raised remain largely parked in FDs, with selective utilization ongoing as opportunities arise.

- Company aims to grow at a rate between 23%-30% annually across key segments. - Domestic own branded business expected to continue 25%+ growth. - CDMO business expected to grow 5%-10% annually. - Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through. - Dermatology (Derma) segment expected to grow from Rs. 12.3 crores to Rs. 30 crores next year and Rs. 45-50 crores in 3 years. - Consolidated revenue guidance for FY26 is around Rs. 450 crores, with a vision to reach Rs. 750 crores by FY28. - New product launches (e.g., NDDS, Oral Therapy) and expansions in regulated markets expected to fuel growth. - Expected positive EBITDA in Dermatology from FY26 onwards. - International markets, including Mexico, Brazil, Philippines, expected to contribute strong growth in coming years.

- The document does not explicitly mention the current or expected order book or pending orders in numeric terms. - Rahul Batra mentions robust business operations with multiple strategic growth plans, indicating strong future demand. - CDMO segment has about 30 clients, with 3 new clients added this year, suggesting ongoing and future order inflows. - The company is actively preparing dossiers for regulatory approvals in multiple export markets (Mexico, Brazil, Thailand, Philippines, Vietnam), indicative of pending orders and potential new market entries. - Transition to Mainboard and capital investments (e.g., new corporate office, API intermediate plant search) demonstrate readiness to handle increased order volumes. - Management emphasizes a robust pipeline for the next 3-4 years and consistent growth of 23%-30% annually across segments, signifying a positive outlook on order inflow.